|Assessment Status||Full HTA Assessment|
|Indication||For the maintenance treatment of severe Chronic Obstructive Pulmonary Disease associated with chronic bronchitis in patients with a history of frequent exacerbations.|
|Full submission received from Applicant||11/06/2010|
|NCPE assessment completed||03/11/2010|
|NCPE assessment outcome||Reimbursement not Recommended|
We do not recommend reimbursement of Roflumilast (Daxas®) under the Community Drugs Schemes.